Adult krabbe disease that was successfully treated with intravenous immunoglobulin

5Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Krabbe disease involves the accumulation of neurotoxic metabolites due to lysosomal galactocerebrosidase enzyme deficiency, which results in widespread demyelination of central and peripheral nerves. Generally, Krabbe disease presents as spastic paraplegia with a slow progressive course; however, some cases may show clinical symptoms similar to those of chronic inflammatory demyelinating polyneuropathy (CIDP). No previously reported studies have investigated the efficacy of intravenous immunoglobulin (IVIg) for treating Krabbe disease, and reporting a case involving IVIg treatment may be informative in the clinical setting. A 14-year-old girl who developed Guillain-Barre syndrome-like limb weakness was administered IVIg, and her limb weakness improved. At 16 years old, she developed abnormal sensory perception and weakness of both upper limbs. A nerve conduction study revealed demyelination, which led us to suspect CIDP. IVIg was administered, and her symptoms gradually improved. A nerve biopsy, enzyme activity, and genetic test results indicated adult Krabbe disease. In some cases, IVIg may be an effective treatment for Krabbe disease.

Cite

CITATION STYLE

APA

Fukazawa, R., Takeuchi, H., Oka, N., Shibuya, T., Sakai, N., & Fujii, A. (2021). Adult krabbe disease that was successfully treated with intravenous immunoglobulin. Internal Medicine, 60(8), 1283–1286. https://doi.org/10.2169/internalmedicine.6094-20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free